23 completed, 3 recruiting, 3 terminated, 2 withdrawn. 14 Phase 2, 9 Phase 3, 6 Phase 4, 4 Phase 1.
Follow valbenazine: new trials by email Literature Review of valbenazine trials Research Report on valbenazine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Valbenazine in Obsessive Compulsive Disorder Valbenazine, Placebo - Obsessive-Compulsive Disorder | Phase 2 | Not yet recruiting | University of Chicago | 30 | 2026-06-01 | 2026-06-10 |
| A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Valbenazine - Schizophrenia, Schizoaffective Disorder | Phase 4 | Recruiting | Neurocrine Biosciences | 100 | 2025-08-29 | 2026-09-18 |
| Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities Valbenazine Oral Capsule - Tardive Dyskinesia, Intellectual Disability | Phase 4 | Withdrawn | Stephen Ruedrich | 2025-01-01 | 2024-10-24 | |
| Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical Dystonia Valbenazine, Placebo - Cervical Dystonia | Phase 2 | Recruiting | Virginia Commonwealth University | 20 | 2024-12-17 | 2026-06-04 |
| Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine Valbenazine - Tardive Dyskinesia | Phase 1 | Withdrawn | Yale University | 2024-10-18 | 2025-07-11 | |
| Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada Valbenazine - Chorea, Huntington | Phase 3 | Enrolling by invitation | Neurocrine Biosciences | 7 | 2024-04-24 | 2026-06-18 |
| Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults Valbenazine Oral Capsule, Placebo Oral capsule - Trichotillomania (Hair-Pulling Disorder) | Phase 2 | Recruiting | Yale University | 20 | 2024-02-02 | 2026-02-03 |
| Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia Valbenazine - Schizophrenia, Schizoaffective Disorder | Phase 4 | Completed | Neurocrine Biosciences | 59 | 2023-05-09 | 2026-01-16 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Valbenazine, Placebo - Schizophrenia | Phase 3 | Terminated | Neurocrine Biosciences | 8 | 2023-01-05 | 2024-11-12 |
| Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy Placebo, Valbenazine - Dyskinesia, Cerebral Palsy | Phase 3 | Completed | Neurocrine Biosciences | 86 | 2022-04-15 | 2026-04-29 |
| Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia Placebo, Valbenazine - Schizophrenia | Phase 3 | Completed | Neurocrine Biosciences | 442 | 2021-11-29 | 2026-02-10 |
| Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia Ingrezza Pill - Cervical Dystonia | Phase 4 | Completed | The Orthopedic Foundation | 20 | 2021-10-19 | 2023-10-06 |
| Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease Valbenazine - Chorea, Huntington | Phase 3 | Completed | Neurocrine Biosciences | 154 | 2020-09-18 | 2026-06-17 |
| Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease Valbenazine, Placebo - Chorea, Huntington | Phase 3 | Completed | Neurocrine Biosciences | 128 | 2019-11-13 | 2023-10-11 |
| Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia Valbenazine, Placebo oral capsule - Tardive Dyskinesia (TD) | Phase 4 | Completed | Neurocrine Biosciences | 135 | 2019-03-18 | 2021-04-20 |
| Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome NBI-98854 - Tourette Syndrome | Phase 2 | Terminated | Neurocrine Biosciences | 6 | 2018-10-17 | 2022-04-19 |
| The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine Valbenazine, Placebo oral capsule - Tardive Dyskinesia (TD) | Phase 4 | Completed | Neurocrine Biosciences | 89 | 2018-09-14 | 2020-06-04 |
| Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome Valbenazine, Placebo oral capsule - Tourette Syndrome | Phase 2 | Terminated | Neurocrine Biosciences | 81 | 2018-04-17 | 2022-05-17 |
| Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Valbenazine - Tourette Syndrome | Phase 2 | Completed | Neurocrine Biosciences | 85 | 2018-02-08 | 2022-02-23 |
| Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Valbenazine, Placebo oral capsule - Tourette Syndrome | Phase 2 | Completed | Neurocrine Biosciences | 127 | 2017-10-05 | 2021-06-28 |
Showing 20 of 33. Sign in to see all of them.
Tardive Dyskinesia (13) · Tourette Syndrome (8) · Schizophrenia (4) · Huntington Disease (3) · Bipolar Disorder (2) · Chorea (2) · Depressive Disorder, Major (2) · Movement Disorders (2) · Psychotic Disorders (2) · Torticollis (2) · Athetosis (1) · Caregiver Burden (1) · Cerebral Palsy (1) · Developmental Disabilities (1) · Dyskinesias (1)
Neurocrine Biosciences (27) · Yale University (2) · Stephen Ruedrich (1) · The Orthopedic Foundation (1) · University of Chicago (1) · Virginia Commonwealth University (1)
United States (30) · Puerto Rico (10) · Canada (6) · Argentina (2) · Belgium (1) · Brazil (1) · Bulgaria (1) · Israel (1) · Italy (1) · Mexico (1) · Poland (1) · Portugal (1) · Serbia (1) · Spain (1)
Chris O'Brien, MD (6) · Brian Berman (1) · Christopher O'Brien, MD (1) · John De Figueiredo, MD (1) · Jon E Grant, MD, JD, MPH (1) · Martin Taylor, DO, PHD (1) · Michael H. Bloch, MD (1) · Stephen Ruedrich, MD (1)
PMID 31617235, PMID 28404690, PMID 40265997, PMID 28320223, PMID 29141124, PMID 30695293, PMID 32250312, PMID 32419679, PMID 37210099